Hub : Traits

Time >=10cm from walls, locomotor time 1

Time spent at least 10 cm from the chamber walls in time 1

Tags: Behavior · Locomotion

Project: u01_suzanne_mitchell

2 loci · 2 genes with independent associations · 2 total associated genes

Significant Loci

#	Chr	Start pos	End pos	# assoc genes	# joint models	Best TWAS P	Best GWAS P	Cond GWAS P	Joint genes
1	9	24497174	25018277	1	1	6.64e-08	3.78e-03	1.0e+00	Rims1
2	15	26118407	27192736	1	1	2.35e-08	1.64e-02	1.7e-08	AABR07017874.1

Pleiotropic Associations

Trait	Chi2 ratio	# genes+	# genes++	% genes++	Corr	Corr P	Genes
Right kidney weight	1.91	1	0	0	0	1e+00	Rims1
Liver weight, right	3.23	1	0	0	0	1e+00	Rims1
Delay discounting total patch changes 24 sec	4.37	1	0	0	0	1e+00	AABR07017874.1
Delay discounting time to switch 0 sec	4.19	1	0	0	0	1e+00	AABR07017874.1
Delay discounting water rate 0 sec	5.7	1	0	0	0	1e+00	AABR07017874.1
Delay discounting water rate 6 sec	6.15	1	0	0	0	1e+00	AABR07017874.1
Light reinforcement 2	7.69	1	0	0	0	1e+00	Rims1
Conditioned reinforcement - actives	6.77	1	0	0	0	1e+00	AABR07017874.1
Conditioned reinforcement - inactives	5.55	1	0	0	0	1e+00	Rims1
Intermitt. access day 1 inactive lever presses	15.13	1	0	0	0	1e+00	Rims1
Intermitt. access day 15 inactive lever presses	7.68	1	0	0	0	1e+00	Rims1
Intermittent access day 1 total infusions	5.12	1	0	0	0	1e+00	AABR07017874.1
Intermittent access day 15 total infusions	8.02	1	0	0	0	1e+00	AABR07017874.1
Intermittent access total infusions	4.68	1	0	0	0	1e+00	Rims1
Intermittent access standard deviation	5.97	1	0	0	0	1e+00	AABR07017874.1
Post-drug Anxiety	8.77	1	0	0	0	1e+00	AABR07017874.1
Baseline Anxiety	6.15	1	0	0	0	1e+00	AABR07017874.1
Lifetime Intake	4.54	1	0	0	0	1e+00	Rims1
Incentive Sensitization - Responses	8.42	1	0	0	0	1e+00	Rims1
Incentive Sensitization - Breakpoint	6.3	1	0	0	0	1e+00	Rims1
Progressive ratio test 1 active lever presses	11.71	1	0	0	0	1e+00	Rims1
Progressive ratio test 1 breakpoint	14.08	1	0	0	0	1e+00	Rims1
Progressive ratio test 2 active lever presses	14.22	1	0	0	0	1e+00	Rims1
Progressive ratio test 2 breakpoint	16.36	1	0	0	0	1e+00	Rims1
Short access day 10 total inactive lever presses	20.55	2	1	50	0	1e+00	Rims1 AABR07017874.1
Short access total infusions	5.45	1	0	0	0	1e+00	Rims1
One hour access (0.3 mA shock)	4.85	1	0	0	0	1e+00	Rims1
Locomotion velocity, session 3	6.63	1	0	0	0	1e+00	Rims1
Stereotopy head waving bouts, day 7	5.96	1	0	0	0	1e+00	AABR07017874.1
Stereotopy head waving duration, day 7	4.67	1	0	0	0	1e+00	AABR07017874.1
Degree of sensitization stereotypy	5	1	0	0	0	1e+00	AABR07017874.1
Distance traveled before self-admin	5.8	1	0	0	0	1e+00	Rims1
Distance traveled after self-admin	4.99	1	0	0	0	1e+00	Rims1
Extinction: sum of active levers before priming	27.4	1	1	50	0	1e+00	Rims1
Delta distance traveled before/after self-admin	12.16	1	0	0	0	1e+00	Rims1
Delta ambulatory time before/after self-admin	5.33	1	0	0	0	1e+00	Rims1
Time in closed arm after self-admin	7.54	1	0	0	0	1e+00	Rims1
Time to tail flick, vehicle, before self-admin	9.4	1	0	0	0	1e+00	Rims1
Ambulatory time before self-admin	6.32	1	0	0	0	1e+00	AABR07017874.1
Total heroin consumption	9.39	1	0	0	0	1e+00	AABR07017874.1
Bouts of movement, locomotor time 1	5.95	1	0	0	0	1e+00	Rims1
Total resting periods, locomotor time 1	6.96	1	0	0	0	1e+00	Rims1
Vertical activity count, locomotor time 1	6.12	1	0	0	0	1e+00	Rims1
Time >=10cm from walls, locomotor time 2	6.16	1	0	0	0	1e+00	AABR07017874.1
Bouts of movement, locomotor time 2	16.19	2	1	50	0	1e+00	Rims1 AABR07017874.1
Total resting periods, locomotor time 2	30.91	1	1	50	0	1e+00	Rims1
Rest time, locomotor task time 2	4.5	1	0	0	0	1e+00	Rims1
Distance moved, locomotor task time 2	20.54	1	0	0	0	1e+00	AABR07017874.1
Vertical activity count, locomotor time 2	5.12	1	0	0	0	1e+00	AABR07017874.1
Locomotion in novel chamber	4.57	1	0	0	0	1e+00	AABR07017874.1
Locomotion in novel chamber post-restriction	5.15	1	0	0	0	1e+00	Rims1
Latency to leave start box in cocaine runway, M	8.77	1	0	0	0	1e+00	AABR07017874.1

Associations by panel

Tissue	RNA modality	# hits	% hits/tests	Avg chisq
Adipose	alternative polyA	0	0	1.07
Adipose	alternative TSS	0	0	1.02
Adipose	gene expression	0	0	0.99
Adipose	isoform ratio	0	0	1.04
Adipose	intron excision ratio	0	0	1.05
Adipose	mRNA stability	0	0	0.99
BLA	alternative polyA	0	0	0.99
BLA	alternative TSS	0	0	0.99
BLA	gene expression	0	0	0.99
BLA	isoform ratio	0	0	1.08
BLA	intron excision ratio	0	0	1.03
BLA	mRNA stability	0	0	1.04
Brain	alternative polyA	0	0	1
Brain	alternative TSS	0	0	0.98
Brain	gene expression	1	0	0.97
Brain	isoform ratio	0	0	1.01
Brain	intron excision ratio	0	0	0.98
Brain	mRNA stability	0	0	0.98
Eye	alternative polyA	0	0	1.21
Eye	alternative TSS	0	0	0.88
Eye	gene expression	0	0	1.04
Eye	isoform ratio	0	0	0.96
Eye	intron excision ratio	0	0	0.92
Eye	mRNA stability	0	0	0.92
IL	alternative polyA	0	0	1.06
IL	alternative TSS	0	0	1.06
IL	gene expression	0	0	0.95
IL	isoform ratio	0	0	0.96
IL	intron excision ratio	0	0	1.15
IL	mRNA stability	0	0	0.97
LHb	alternative polyA	0	0	0.99
LHb	alternative TSS	0	0	1.23
LHb	gene expression	0	0	0.98
LHb	isoform ratio	0	0	0.99
LHb	intron excision ratio	0	0	1.05
LHb	mRNA stability	0	0	1
Liver	alternative polyA	0	0	1.01
Liver	alternative TSS	0	0	1.14
Liver	gene expression	0	0	1.01
Liver	isoform ratio	0	0	1.04
Liver	intron excision ratio	0	0	1.04
Liver	mRNA stability	0	0	0.99
NAcc	alternative polyA	0	0	0.95
NAcc	alternative TSS	0	0	1.07
NAcc	gene expression	1	0	0.98
NAcc	isoform ratio	0	0	1
NAcc	intron excision ratio	0	0	1.03
NAcc	mRNA stability	0	0	1.01
OFC	alternative polyA	0	0	1.02
OFC	alternative TSS	0	0	0.91
OFC	gene expression	0	0	0.99
OFC	isoform ratio	0	0	0.97
OFC	intron excision ratio	0	0	1.1
OFC	mRNA stability	0	0	1.06
PL	alternative polyA	0	0	1.09
PL	alternative TSS	0	0	1.02
PL	gene expression	0	0	0.99
PL	isoform ratio	0	0	1.02
PL	intron excision ratio	0	0	1.08
PL	mRNA stability	0	0	1